Navigation Links
Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
Date:9/16/2009

15 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

ABOUT KRYSTEXXA(TM)

KRYSTEXXA(TM) (pegloticase) is a PEGylated uricase enzyme intended for the treatment of chronic gout in patients refractory to conventional therapy. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. Savient has developed one product: KRYSTEXXA(TM) (pegloticase) which is a PEGylated uricase enzyme intended for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: http://www.savient.com. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

FORWARD-LOOKING LANGUAGE

All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, tren
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
2. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
3. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
4. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
5. Savient Announces Appointment of David Gionco as Chief Financial Officer
6. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
7. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Savient Submits Biologics License Application (BLA) for pegloticase
9. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
10. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
11. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating ... own time adjusting, tweaking and testing virtual models and ... for judging. , “I enjoyed being involved as a ... “The entries showed a commendable range exploring the technical ... print medium and the creativity of the contestants.” , ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 In ... cost-effective tools to address sales, training and consumer ... has developed innovative mobile applications to turn their ... the agency’s latest customized mobile app creations, are ... . , In partnership with Toyota, StudioPMG created ...
(Date:10/1/2014)... BOSTON, MA (PRWEB) September 30, 2014 ... company, SoundConnect announces four new-hosted collaboration ... innovative bundles deliver high quality conferencing experiences for ... collaboration packages to choose from, businesses have optimized ... bundled solutions include audio only minutes ...
(Date:10/1/2014)... 01, 2014 TeselaGen Biotechnology ... Foundation to expand their bioCAD/CAM software suite, which uses ... DNA. The Small Business Innovation Research Phase II grant ... under exclusive license from the Lawrence Berkeley National Laboratory. ... , an LBNL laboratory that develops alternative fuel technologies ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... Seamless Performance Between GeneChip Scanner 3000 ... , ... GeneChip Instrument System is the most advanced microarray analysis platform ... array manufacturing processes have enabled Affymetrix to produce expression probe arrays with ...
... Spectrometry Application Note , Melissa ... Introduction , ... complex mixtures is one of the key objectives for the use of ... ion trap systems, such as the Finnigan LCQ Deca XP Plus and ...
... Chromatography and Mass Spectrometry Application Note , ... Quantum Discovery Enhanced Mass- Resolution , Xiaoying ... Walter Korfmacher 1 , ... NJ, USA; 2 Thermo Electron Corporation, Somerset, NJ, USA , ...
Cached Biology Technology:The New Affymetrix GeneChip Scanner 3000 2The New Affymetrix GeneChip Scanner 3000 3The New Affymetrix GeneChip Scanner 3000 4The New Affymetrix GeneChip Scanner 3000 5The New Affymetrix GeneChip Scanner 3000 6The New Affymetrix GeneChip Scanner 3000 7The New Affymetrix GeneChip Scanner 3000 8The New Affymetrix GeneChip Scanner 3000 9The New Affymetrix GeneChip Scanner 3000 10The New Affymetrix GeneChip Scanner 3000 11The New Affymetrix GeneChip Scanner 3000 12The New Affymetrix GeneChip Scanner 3000 13The New Affymetrix GeneChip Scanner 3000 14The New Affymetrix GeneChip Scanner 3000 15Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 2Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 3Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 4Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 2Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 3Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 4Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 5Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 6
(Date:9/30/2014)... of Health (NIH) awarded Lawrence Livermore National Laboratory ... array system that will enable researchers to better ... and scale. , LLNL,s grant-funded project is part ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... understanding of the human mind and uncover ways ...
(Date:9/30/2014)... of environmental scientists and engineers, led by Clemson ... three-year, $5.25 million grant from the U.S. Department ... to make a direct positive impact on South ... disposal of radioactive contaminants. , "Understanding the scientific ... with environmental aspects of nuclear technologies is imperative ...
(Date:9/30/2014)... Medicine reports positive results of a phase 1 ... of lung cancer marked by rearrangement of the gene ... advanced non-small cell lung cancer testing positive for ROS1 ... 3 complete responses and 33 partial responses. Median progression-free ... to resume its growth after being slowed by treatment ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... little research has been done on it, now may have ... involving people, the acai (ah-sigh-EE) berry has proven its ability ... as juice and pulp. That finding, by a team of ... of the Journal of Agricultural and Food Chemistry ., ...
... a chance to take root and spread, scientists are ... prevention. Leading experts from around the globe are gathering ... promising new field, with the hope this work will ... you take advantage of the meeting,s scientific abstracts and ...
... al.report in the Journal of Cell Biology ... movement in tumor cells., On 2D surfaces, cells may ... the cell to the extracellular matrix, are known to ... been unclear. Recent work has suggested that an integrin ...
Cached Biology News:Research shows Brazilian acai berry antioxidants absorbed by human body 2Research shows Brazilian acai berry antioxidants absorbed by human body 3